RT @drdavidliew: Biosimilar vs originator: as switches loom in the US, once again itâs really hard to say we see any d
Tweet Content
Biosimilar vs originator: as switches loom in the US, once again it’s really hard to say we see any differences in drug survival for our RA patients
These data from forced switching in BC, Canada are just like the others - biosimilars are business as usual. POS0567 #EULAR2023 https://t.co/Ebl1hTM4qE
Show on Archive Page
On
Display in Search Results
On
PDQ
Off